Phase II study of chlorozotocin in islet cell carcinoma. A southwest Oncology Group study

Seventeen patients with islet cell carcinoma received chlorozotocin (CTZ). Nine received 200 mg/m2 IV every 6 weeks and 8 received 100 mg/m2. Responses were seen in eight (2 complete, 5 partial, 1 minor) of 13 patients who had received no prior chemotherapy, and in zero of four who had received prior chemotherapy. Toxicity was mild in most patients and consisted predominantly in myelosuppressions; however, in one patient severe renal failure developed. CTZ may have activity comparable to streptozotocin in this group of patients.